Search

Your search keyword '"Broniscer, Alberto"' showing total 568 results
Start Over Author "Broniscer, Alberto"
568 results on '"Broniscer, Alberto"'

1. Pediatric Brain Tumors: Role of Imaging

Author

Tierradentro-García, Luis Octavio, Sotardi, Susan, Mankad, Kshitij, Broniscer, Alberto, Bhatia, Aashim, Medina, L. Santiago, Series Editor, Applegate, Kimberly E., Series Editor, Blackmore, C. Craig, Series Editor, Otero, Hansel J., editor, and Kaplan, Summer L., editor

Published
2024
Full Text
View/download PDF

2. Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor.

Author

Upadhyaya, Santhosh, Campagne, Olivia, Billups, Catherine, Orr, Brent, Onar-Thomas, Arzu, Tatevossian, Ruth, Mostafavi, Roya, Myers, Jason, Vinitsky, Anna, Moreira, Daniel, Lindsay, Holly, Kilburn, Lindsay, Baxter, Patricia, Smith, Amy, Crawford, John, Partap, Sonia, Bendel, Anne, Aguilera, Dolly, Nichols, Kim, Rampersaud, Evadnie, Ellison, David, Klimo, Paul, Patay, Zoltan, Robinson, Giles, Broniscer, Alberto, Stewart, Clinton, Wetmore, Cynthia, and Gajjar, Amar

Subjects
Aurora kinase A, alisertib, alisertib pharmacokinetics, atypical teratoid/rhabdoid tumor, Child, Humans, Antineoplastic Agents, Rhabdoid Tumor, Azepines, Pyrimidines, Central Nervous System Neoplasms, Aurora Kinase A, Protein Kinase Inhibitors
Abstract

BACKGROUND: Recurrent atypical teratoid/rhabdoid tumor (AT/RT) is, most often, a fatal pediatric malignancy with limited curative options. METHODS: We conducted a phase II study of Aurora kinase A inhibitor alisertib in patients aged 12 months. PFS did not differ by AT/RT molecular groups. Neutropenia was the most common adverse effect (n = 23/30, 77%). The 22 patients who received liquid formulation had a higher mean maximum concentration (Cmax) of 10.1 ± 3.0 µM and faster time to Cmax (Tmax = 1.2 ± 0.7 h) than those who received tablets (Cmax = 5.7 ± 2.4 µM, Tmax = 3.4 ± 1.4 h). CONCLUSIONS: Although the study did not meet predetermined efficacy end point, single-agent alisertib was well tolerated by children with recurrent AT/RT, and SD or PR was observed in approximately a third of the patients.

Published
2023

3. Molecular classification and outcome of children with rare CNS embryonal tumors: results from St. Jude Childrens Research Hospital including the multi-center SJYC07 and SJMB03 clinical trials.

Author

Liu, Anthony, Dhanda, Sandeep, Lin, Tong, Sioson, Edgar, Vasilyeva, Aksana, Gudenas, Brian, Tatevossian, Ruth, Jia, Sujuan, Neale, Geoffrey, Bowers, Daniel, Hassall, Tim, Partap, Sonia, Crawford, John, Chintagumpala, Murali, Bouffet, Eric, McCowage, Geoff, Broniscer, Alberto, Qaddoumi, Ibrahim, Armstrong, Greg, Wright, Karen, Upadhyaya, Santhosh, Vinitsky, Anna, Tinkle, Christopher, Lucas, John, Chiang, Jason, Indelicato, Daniel, Sanders, Robert, Klimo, Paul, Boop, Frederick, Merchant, Thomas, Ellison, David, Northcott, Paul, Orr, Brent, Zhou, Xin, Onar-Thomas, Arzu, Gajjar, Amar, and Robinson, Giles

Subjects
Brain Neoplasms, Central Nervous System Neoplasms, Child, Forkhead Transcription Factors, Glioblastoma, Hospitals, Humans, Neoplasms, Germ Cell and Embryonal, Neuroectodermal Tumors, Primitive
Abstract

Methylation profiling has radically transformed our understanding of tumors previously called central nervous system primitive neuro-ectodermal tumors (CNS-PNET). While this marks a momentous step toward defining key differences, reclassification has thrown treatment into disarray. To shed light on response to therapy and guide clinical decision-making, we report outcomes and molecular features of children with CNS-PNETs from two multi-center risk-adapted studies (SJMB03 for patients ≥ 3 years; SJYC07 for patients

Published
2022

4. The seventh international RASopathies symposium: Pathways to a cure—expanding knowledge, enhancing research, and therapeutic discovery

Author

Kontaridis, Maria I, Roberts, Amy E, Schill, Lisa, Schoyer, Lisa, Stronach, Beth, Andelfinger, Gregor, Aoki, Yoko, Axelrad, Marni E, Bakker, Annette, Bennett, Anton M, Broniscer, Alberto, Castel, Pau, Chang, Caitlin A, Cyganek, Lukas, Das, Tirtha K, Hertog, Jeroen, Galperin, Emilia, Garg, Shruti, Gelb, Bruce D, Gordon, Kristiana, Green, Tamar, Gripp, Karen W, Itkin, Maxim, Kiuru, Maija, Korf, Bruce R, Livingstone, Jeff R, López‐Juárez, Alejandro, Magoulas, Pilar L, Mansour, Sahar, Milner, Theresa, Parker, Elisabeth, Pierpont, Elizabeth I, Plouffe, Kevin, Rauen, Katherine A, Shankar, Suma P, Smith, Shane B, Stevenson, David A, Tartaglia, Marco, Van, Richard, Wagner, Morgan E, Ware, Stephanie M, and Zenker, Martin

Subjects
Pediatric, Genetics, Aetiology, 2.1 Biological and endogenous factors, Good Health and Well Being, Costello Syndrome, Humans, Mitogen-Activated Protein Kinases, Noonan Syndrome, Signal Transduction, ras Proteins, cardiofaciocutaneus syndrome, Costello syndrome, neurofibromatosis, Noonan syndrome, RASopathy, signaling, Clinical Sciences
Abstract

RASopathies are a group of genetic disorders that are caused by genes that affect the canonical Ras/mitogen-activated protein kinase (MAPK) signaling pathway. Despite tremendous progress in understanding the molecular consequences of these genetic anomalies, little movement has been made in translating these findings to the clinic. This year, the seventh International RASopathies Symposium focused on expanding the research knowledge that we have gained over the years to enhance new discoveries in the field, ones that we hope can lead to effective therapeutic treatments. Indeed, for the first time, research efforts are finally being translated to the clinic, with compassionate use of Ras/MAPK pathway inhibitors for the treatment of RASopathies. This biannual meeting, organized by the RASopathies Network, brought together basic scientists, clinicians, clinician scientists, patients, advocates, and their families, as well as representatives from pharmaceutical companies and the National Institutes of Health. A history of RASopathy gene discovery, identification of new disease genes, and the latest research, both at the bench and in the clinic, were discussed.

Published
2022

5. A neurodevelopmental epigenetic programme mediated by SMARCD3–DAB1–Reelin signalling is hijacked to promote medulloblastoma metastasis

Author

Zou, Han, Poore, Bradley, Brown, Emily E., Qian, Jieqi, Xie, Bin, Asimakidou, Evridiki, Razskazovskiy, Vladislav, Ayrapetian, Deanna, Sharma, Vaibhav, Xia, Shunjin, Liu, Fei, Chen, Apeng, Guan, Yongchang, Li, Zhengwei, Wanggou, Siyi, Saulnier, Olivier, Ly, Michelle, Fellows-Mayle, Wendy, Xi, Guifa, Tomita, Tadanori, Resnick, Adam C., Mack, Stephen C., Raabe, Eric H., Eberhart, Charles G., Sun, Dandan, Stronach, Beth E., Agnihotri, Sameer, Kohanbash, Gary, Lu, Songjian, Herrup, Karl, Rich, Jeremy N., Gittes, George K., Broniscer, Alberto, Hu, Zhongliang, Li, Xuejun, Pollack, Ian F., Friedlander, Robert M., Hainer, Sarah J., Taylor, Michael D., and Hu, Baoli

Published
2023
Full Text
View/download PDF

6. Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials.

Author

Upadhyaya, Santhosh, Robinson, Giles, Onar-Thomas, Arzu, Orr, Brent, Johann, Pascal, Wu, Gang, Billups, Catherine, Tatevossian, Ruth, Dhanda, Sandeep, Srinivasan, Ashok, Broniscer, Alberto, Qaddoumi, Ibrahim, Vinitsky, Anna, Armstrong, Gregory, Bendel, Anne, Hassall, Tim, Partap, Sonia, Fisher, Paul, Crawford, John, Chintagumpala, Murali, Bouffet, Eric, Gururangan, Sridharan, Mostafavi, Roya, Sanders, Robert, Klimo, Paul, Patay, Zoltan, Indelicato, Daniel, Nichols, Kim, Boop, Frederick, Merchant, Thomas, Kool, Marcel, Ellison, David, and Gajjar, Amar

Subjects
Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Child, Child, Preschool, DNA Copy Number Variations, DNA Methylation, Diagnosis, Differential, Disease Management, Disease Susceptibility, Female, Germ-Line Mutation, Humans, Infant, Male, Mutation, Prognosis, Rhabdoid Tumor, SMARCB1 Protein, Teratoma, Treatment Outcome
Abstract

PURPOSE: Report relevance of molecular groups to clinicopathologic features, germline SMARCB1/SMARCA4 alterations (GLA), and survival of children with atypical teratoid rhabdoid tumor (ATRT) treated in two multi-institutional clinical trials. MATERIALS AND METHODS: Seventy-four participants with newly diagnosed ATRT were treated in two trials: infants (SJYC07: age < 3 years; n = 52) and children (SJMB03: age 3-21 years; n = 22), using surgery, conventional chemotherapy (infants), or dose-dense chemotherapy with autologous stem cell rescue (children), and age- and risk-adapted radiotherapy [focal (infants) and craniospinal (CSI; children)]. Molecular groups ATRT-MYC (MYC), ATRT-SHH (SHH), and ATRT-TYR (TYR) were determined from tumor DNA methylation profiles. RESULTS: Twenty-four participants (32%) were alive at time of analysis at a median follow-up of 8.4 years (range, 3.1-14.1 years). Methylation profiling classified 64 ATRTs as TYR (n = 21), SHH (n = 30), and MYC (n = 13), SHH group being associated with metastatic disease. Among infants, TYR group had the best overall survival (OS; P = 0.02). However, outcomes did not differ by molecular groups among infants with nonmetastatic (M0) disease. Children with M0 disease and

Published
2021

7. Pediatric bithalamic gliomas have a distinct epigenetic signature and frequent EGFR exon 20 insertions resulting in potential sensitivity to targeted kinase inhibition

Author

Mondal, Gourish, Lee, Julieann C, Ravindranathan, Ajay, Villanueva-Meyer, Javier E, Tran, Quynh T, Allen, Sariah J, Barreto, Jairo, Gupta, Rohit, Doo, Pamela, Van Ziffle, Jessica, Onodera, Courtney, Devine, Patrick, Grenert, James P, Samuel, David, Li, Rong, Metrock, Laura K, Jin, Lee-way, Antony, Reuben, Alashari, Mouied, Cheshier, Samuel, Whipple, Nicholas S, Bruggers, Carol, Raffel, Corey, Gupta, Nalin, Kline, Cassie N, Reddy, Alyssa, Banerjee, Anu, Hall, Matthew D, Mehta, Minesh P, Khatib, Ziad, Maher, Ossama M, Brathwaite, Carole, Pekmezci, Melike, Phillips, Joanna J, Bollen, Andrew W, Tihan, Tarik, Lucas, John T, Broniscer, Alberto, Berger, Mitchel S, Perry, Arie, Orr, Brent A, and Solomon, David A

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Brain Disorders, Rare Diseases, Brain Cancer, Cancer, Genetics, Human Genome, Pediatric, Neurosciences, Orphan Drug, 2.1 Biological and endogenous factors, Aetiology, Adolescent, Antineoplastic Agents, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Child, Child, Preschool, Epigenesis, Genetic, ErbB Receptors, Female, Glioma, Humans, Lung Neoplasms, Male, Mutation, Protein Kinase Inhibitors, Bithalamic glioma, Diffuse midline glioma, EGFR, Histone H3, Pediatric cancer, Molecular neuropathology, Tyrosine kinase inhibitor, Afatinib, Osimertinib, Erlotinib, Trametinib, Neurology & Neurosurgery
Abstract

Brain tumors are the most common solid tumors of childhood, and the genetic drivers and optimal therapeutic strategies for many of the different subtypes remain unknown. Here, we identify that bithalamic gliomas harbor frequent mutations in the EGFR oncogene, only rare histone H3 mutation (in contrast to their unilateral counterparts), and a distinct genome-wide DNA methylation profile compared to all other glioma subtypes studied to date. These EGFR mutations are either small in-frame insertions within exon 20 (intracellular tyrosine kinase domain) or missense mutations within exon 7 (extracellular ligand-binding domain) that occur in the absence of accompanying gene amplification. We find these EGFR mutations are oncogenic in primary astrocyte models and confer sensitivity to specific tyrosine kinase inhibitors dependent on location within the kinase domain or extracellular domain. We initiated treatment with targeted kinase inhibitors in four children whose tumors harbor EGFR mutations with encouraging results. This study identifies a promising genomically-tailored therapeutic strategy for bithalamic gliomas, a lethal and genetically distinct brain tumor of childhood.

Published
2020

8. Gliomatosis cerebri in children: A poor prognostic phenotype of diffuse gliomas with a distinct molecular profile

Author

Nussbaumer, Gunther, primary, Benesch, Martin, additional, Grabovska, Yura, additional, Mackay, Alan, additional, Castel, David, additional, Grill, Jacques, additional, Alonso, Marta M, additional, Antonelli, Manila, additional, Bailey, Simon, additional, Baugh, Joshua N, additional, Biassoni, Veronica, additional, Blattner Johnson, Mirjam, additional, Broniscer, Alberto, additional, Carai, Andrea, additional, Colafati, Giovanna Stefania, additional, Colditz, Niclas, additional, Corbacioglu, Selim, additional, Crampsie, Shauna, additional, Entz-Werle, Natacha, additional, Eyrich, Matthias, additional, Friker, Lea L, additional, Frühwald, Michael C, additional, Garrè, Maria Luisa, additional, Gerber, Nicolas U, additional, Giangaspero, Felice, additional, Gil-da-Costa, Maria J, additional, Graf, Norbert, additional, Hargrave, Darren, additional, Hauser, Peter, additional, Herrlinger, Ulrich, additional, Hoffmann, Marion, additional, Hulleman, Esther, additional, Izquierdo, Elisa, additional, Jacobs, Sandra, additional, Karremann, Michael, additional, Kattamis, Antonis, additional, Kebudi, Rejin, additional, Kortmann, Rolf-Dieter, additional, Kwiecien, Robert, additional, Massimino, Maura, additional, Mastronuzzi, Angela, additional, Miele, Evelina, additional, Morana, Giovanni, additional, Noack, Claudia M, additional, Pentikainen, Virve, additional, Perwein, Thomas, additional, Pfister, Stefan M, additional, Pietsch, Torsten, additional, Roka, Kleoniki, additional, Rossi, Sabrina, additional, Rutkowski, Stefan, additional, Schiavello, Elisabetta, additional, Seidel, Clemens, additional, Štěrba, Jaroslav, additional, Sturm, Dominik, additional, Sumerauer, David, additional, Tacke, Anna, additional, Temelso, Sara, additional, Valentini, Chiara, additional, van Vuurden, Dannis, additional, Varlet, Pascale, additional, Veldhuijzen van Zanten, Sophie E M, additional, Vinci, Maria, additional, von Bueren, André O, additional, Warmuth-Metz, Monika, additional, Wesseling, Pieter, additional, Wiese, Maria, additional, Wolff, Johannes E A, additional, Zamecnik, Josef, additional, Morales La Madrid, Andrés, additional, Bison, Brigitte, additional, Gielen, Gerrit H, additional, Jones, David T W, additional, Jones, Chris, additional, and Kramm, Christof M, additional

Published
2024
Full Text
View/download PDF

9. Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome

Author

Golbourn, Brian J., Halbert, Matthew E., Halligan, Katharine, Varadharajan, Srinidhi, Krug, Brian, Mbah, Nneka E., Kabir, Nisha, Stanton, Ann-Catherine J., Locke, Abigail L., Casillo, Stephanie M., Zhao, Yanhua, Sanders, Lauren M., Cheney, Allison, Mullett, Steven J., Chen, Apeng, Wassell, Michelle, Andren, Anthony, Perez, Jennifer, Jane, Esther P., Premkumar, Daniel R. David, Koncar, Robert F., Mirhadi, Shideh, McCarl, Lauren H., Chang, Yue-Fang, Wu, Yijen L., Gatesman, Taylor A., Cruz, Andrea F., Zapotocky, Michal, Hu, Baoli, Kohanbash, Gary, Wang, Xiuxing, Vartanian, Alenoush, Moran, Michael F., Lieberman, Frank, Amankulor, Nduka M., Wendell, Stacy G., Vaske, Olena M., Panigrahy, Ashok, Felker, James, Bertrand, Kelsey C., Kleinman, Claudia L., Rich, Jeremy N., Friedlander, Robert M., Broniscer, Alberto, Lyssiotis, Costas, Jabado, Nada, Pollack, Ian F., Mack, Stephen C., and Agnihotri, Sameer

Published
2022
Full Text
View/download PDF

12. Patient-derived models recapitulate heterogeneity of molecular signatures and drug response in pediatric high-grade glioma

Author

He, Chen, Xu, Ke, Zhu, Xiaoyan, Dunphy, Paige S., Gudenas, Brian, Lin, Wenwei, Twarog, Nathaniel, Hover, Laura D., Kwon, Chang-Hyuk, Kasper, Lawryn H., Zhang, Junyuan, Li, Xiaoyu, Dalton, James, Jonchere, Barbara, Mercer, Kimberly S., Currier, Duane G., Caufield, William, Wang, Yingzhe, Xie, Jia, Broniscer, Alberto, Wetmore, Cynthia, Upadhyaya, Santhosh A., Qaddoumi, Ibrahim, Klimo, Paul, Boop, Frederick, Gajjar, Amar, Zhang, Jinghui, Orr, Brent A., Robinson, Giles W., Monje, Michelle, Freeman III, Burgess B., Roussel, Martine F., Northcott, Paul A., Chen, Taosheng, Rankovic, Zoran, Wu, Gang, Chiang, Jason, Tinkle, Christopher L., Shelat, Anang A., and Baker, Suzanne J.

Published
2021
Full Text
View/download PDF

15. Author Correction: Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome

Author

Golbourn, Brian J., Halbert, Matthew E., Halligan, Katharine, Varadharajan, Srinidhi, Krug, Brian, Mbah, Nneka E., Kabir, Nisha, Stanton, Ann-Catherine J., Locke, Abigail L., Casillo, Stephanie M., Zhao, Yanhua, Sanders, Lauren M., Cheney, Allison, Mullett, Steven J., Chen, Apeng, Wassell, Michelle, Andren, Anthony, Perez, Jennifer, Jane, Esther P., Premkumar, Daniel R. David, Koncar, Robert F., Mirhadi, Shideh, McCarl, Lauren H., Chang, Yue-Fang, Wu, Yijen L., Gatesman, Taylor A., Cruz, Andrea F., Zapotocky, Michal, Hu, Baoli, Kohanbash, Gary, Wang, Xiuxing, Vartanian, Alenoush, Moran, Michael F., Lieberman, Frank, Amankulor, Nduka M., Wendell, Stacy G., Vaske, Olena M., Panigrahy, Ashok, Felker, James, Bertrand, Kelsey C., Kleinman, Claudia L., Rich, Jeremy N., Friedlander, Robert M., Broniscer, Alberto, Lyssiotis, Costas, Jabado, Nada, Pollack, Ian F., Mack, Stephen C., and Agnihotri, Sameer

Published
2022
Full Text
View/download PDF

16. Phase II Trial of Erlotinib during and after Radiotherapy in Children with Newly Diagnosed High-Grade Gliomas.

Author

Qaddoumi, Ibrahim, Kocak, Mehmet, Pai Panandiker, Atmaram, Armstrong, Gregory, Wetmore, Cynthia, Crawford, John, Lin, Tong, Boyett, James, Kun, Larry, Boop, Fredrick, Merchant, Thomas, Ellison, David, Gajjar, Amar, and Broniscer, Alberto

Subjects
epidermal growth factor receptor, erlotinib, high-grade glioma, pediatric, phase II, radiotherapy
Abstract

BACKGROUND: Epidermal growth factor receptor is overexpressed in most pediatric high-grade gliomas (HGG). Since erlotinib had shown activity in adults with HGG, we conducted a phase II trial of erlotinib and local radiotherapy (RT) in children with newly diagnosed HGG. METHODS: Following maximum surgical resection, patients between 3 and 21 years with non-metastatic HGG received local RT at 59.4 Gy (54 Gy for spinal tumors and those with ≥70% brain involvement). Erlotinib started on day 1 of RT (120 mg/m(2) per day) and continued for 2 years unless there was tumor progression or intolerable toxicities. The 2-year progression-free survival (PFS) was estimated for patients with intracranial anaplastic astrocytoma (AA) and glioblastoma (GBM). RESULTS: Median age at diagnosis for 41 patients with intracranial tumors (21 with GBM and 20 with AA) was 10.9 years (range, 3.3-19 years). The 2-year PFS for patients with AA and GBM was 15 ± 7 and 19 ± 8%, respectively. Only five patients remained alive without tumor progression. Twenty-six patients had at least one grade 3 or 4 toxicity irrespective of association with erlotinib; only four required dose modifications. The main toxicities were gastrointestinal (n = 11), dermatologic (n = 5), and metabolic (n = 4). One patient with gliomatosis cerebri who required prolonged corticosteroids died of septic shock associated with pancreatitis. CONCLUSION: Although therapy with erlotinib was mostly well-tolerated, it did not change the poor outcome of our patients. Our results showed that erlotinib is not a promising medication in the treatment of children with intracranial AA and GBM.

Published
2014

18. H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo

Author

Silveira, André B., Kasper, Lawryn H., Fan, Yiping, Jin, Hongjian, Wu, Gang, Shaw, Timothy I., Zhu, Xiaoyan, Larson, Jon D., Easton, John, Shao, Ying, Yergeau, Donald A., Rosencrance, Celeste, Boggs, Kristy, Rusch, Michael C., Ding, Liang, Zhang, Junyuan, Finkelstein, David, Noyes, Rachel M., Russell, Brent L., Xu, Beisi, Broniscer, Alberto, Wetmore, Cynthia, Pounds, Stanley B., Ellison, David W., Zhang, Jinghui, and Baker, Suzanne J.

Published
2019
Full Text
View/download PDF

20. High-grade glioma in infants and young children is histologically, molecularly, and clinically diverse: Results from the SJYC07 trial and institutional experience

Author

Chiang, Jason, primary, Bagchi, Aditi, additional, Li, Xiaoyu, additional, Dhanda, Sandeep K, additional, Huang, Jie, additional, Pinto, Soniya N, additional, Sioson, Edgar, additional, Dalton, James, additional, Tatevossian, Ruth G, additional, Jia, Sujuan, additional, Partap, Sonia, additional, Fisher, Paul G, additional, Bowers, Daniel C, additional, Hassall, Timothy E G, additional, Lu, Congyu, additional, Zaldivar-Peraza, Airen, additional, Wright, Karen D, additional, Broniscer, Alberto, additional, Qaddoumi, Ibrahim, additional, Upadhyaya, Santhosh A, additional, Vinitsky, Anna, additional, Sabin, Noah D, additional, Orr, Brent A, additional, Klimo, Paul, additional, Boop, Frederick A, additional, Ashford, Jason M, additional, Conklin, Heather M, additional, Onar-Thomas, Arzu, additional, Zhou, Xin, additional, Ellison, David W, additional, Gajjar, Amar, additional, and Robinson, Giles W, additional

Published
2023
Full Text
View/download PDF

23. High-grade glioma in infants and young children is histologically, molecularly, and clinically diverse: Results from the SJYC07 trial and institutional experience.

Author

Chiang, Jason, Bagchi, Aditi, Li, Xiaoyu, Dhanda, Sandeep K, Huang, Jie, Pinto, Soniya N, Sioson, Edgar, Dalton, James, Tatevossian, Ruth G, Jia, Sujuan, Partap, Sonia, Fisher, Paul G, Bowers, Daniel C, Hassall, Timothy E G, Lu, Congyu, Zaldivar-Peraza, Airen, Wright, Karen D, Broniscer, Alberto, Qaddoumi, Ibrahim, and Upadhyaya, Santhosh A

Published
2024
Full Text
View/download PDF

26. Figure S2 from Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation–Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study

Author

Hargrave, Darren R., primary, Bouffet, Eric, primary, Tabori, Uri, primary, Broniscer, Alberto, primary, Cohen, Kenneth J., primary, Hansford, Jordan R., primary, Geoerger, Birgit, primary, Hingorani, Pooja, primary, Dunkel, Ira J., primary, Russo, Mark W., primary, Tseng, Lillian, primary, Dasgupta, Kohinoor, primary, Gasal, Eduard, primary, Whitlock, James A., primary, and Kieran, Mark W., primary

Published
2023
Full Text
View/download PDF

27. Table S3 from A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation–Positive Solid Tumors

Author

Kieran, Mark W., primary, Geoerger, Birgit, primary, Dunkel, Ira J., primary, Broniscer, Alberto, primary, Hargrave, Darren, primary, Hingorani, Pooja, primary, Aerts, Isabelle, primary, Bertozzi, Anne-Isabelle, primary, Cohen, Kenneth J., primary, Hummel, Trent R., primary, Shen, Violet, primary, Bouffet, Eric, primary, Pratilas, Christine A., primary, Pearson, Andrew D.J., primary, Tseng, Lillian, primary, Nebot, Noelia, primary, Green, Steven, primary, Russo, Mark W., primary, and Whitlock, James A., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Methods from Phase I Trial, Pharmacokinetics, and Pharmacodynamics of Vandetanib and Dasatinib in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma

Author

Broniscer, Alberto, primary, Baker, Sharyn D., primary, Wetmore, Cynthia, primary, Pai Panandiker, Atmaram S., primary, Huang, Jie, primary, Davidoff, Andrew M., primary, Onar-Thomas, Arzu, primary, Panetta, John C., primary, Chin, Thomas K., primary, Merchant, Thomas E., primary, Baker, Justin N., primary, Kaste, Sue C., primary, Gajjar, Amar, primary, and Stewart, Clinton F., primary

Published
2023
Full Text
View/download PDF

29. Supplementary Figures from Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials

Author

Upadhyaya, Santhosh A., primary, Robinson, Giles W., primary, Onar-Thomas, Arzu, primary, Orr, Brent A., primary, Johann, Pascal, primary, Wu, Gang, primary, Billups, Catherine A., primary, Tatevossian, Ruth G., primary, Dhanda, Sandeep Kumar, primary, Srinivasan, Ashok, primary, Broniscer, Alberto, primary, Qaddoumi, Ibrahim, primary, Vinitsky, Anna, primary, Armstrong, Gregory T., primary, Bendel, Anne E., primary, Hassall, Tim, primary, Partap, Sonia, primary, Fisher, Paul G., primary, Crawford, John R., primary, Chintagumpala, Murali, primary, Bouffet, Eric, primary, Gururangan, Sridharan, primary, Mostafavi, Roya, primary, Sanders, Robert P., primary, Klimo, Paul, primary, Patay, Zoltan, primary, Indelicato, Daniel J., primary, Nichols, Kim E., primary, Boop, Frederick A., primary, Merchant, Thomas E., primary, Kool, Marcel, primary, Ellison, David W., primary, and Gajjar, Amar, primary

Published
2023
Full Text
View/download PDF

30. Supplementary Table 2 from Novel Oncogenic PDGFRA Mutations in Pediatric High-Grade Gliomas

Author

Paugh, Barbara S., primary, Zhu, Xiaoyan, primary, Qu, Chunxu, primary, Endersby, Raelene, primary, Diaz, Alexander K., primary, Zhang, Junyuan, primary, Bax, Dorine A., primary, Carvalho, Diana, primary, Reis, Rui M., primary, Onar-Thomas, Arzu, primary, Broniscer, Alberto, primary, Wetmore, Cynthia, primary, Zhang, Jinghui, primary, Jones, Chris, primary, Ellison, David W., primary, and Baker, Suzanne J., primary

Published
2023
Full Text
View/download PDF

31. Data from Novel Oncogenic PDGFRA Mutations in Pediatric High-Grade Gliomas

Author

Paugh, Barbara S., primary, Zhu, Xiaoyan, primary, Qu, Chunxu, primary, Endersby, Raelene, primary, Diaz, Alexander K., primary, Zhang, Junyuan, primary, Bax, Dorine A., primary, Carvalho, Diana, primary, Reis, Rui M., primary, Onar-Thomas, Arzu, primary, Broniscer, Alberto, primary, Wetmore, Cynthia, primary, Zhang, Jinghui, primary, Jones, Chris, primary, Ellison, David W., primary, and Baker, Suzanne J., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Table 1 from Novel Oncogenic PDGFRA Mutations in Pediatric High-Grade Gliomas

Author

Paugh, Barbara S., primary, Zhu, Xiaoyan, primary, Qu, Chunxu, primary, Endersby, Raelene, primary, Diaz, Alexander K., primary, Zhang, Junyuan, primary, Bax, Dorine A., primary, Carvalho, Diana, primary, Reis, Rui M., primary, Onar-Thomas, Arzu, primary, Broniscer, Alberto, primary, Wetmore, Cynthia, primary, Zhang, Jinghui, primary, Jones, Chris, primary, Ellison, David W., primary, and Baker, Suzanne J., primary

Published
2023
Full Text
View/download PDF

33. Supplementary Table 3 from Novel Oncogenic PDGFRA Mutations in Pediatric High-Grade Gliomas

Author

Paugh, Barbara S., primary, Zhu, Xiaoyan, primary, Qu, Chunxu, primary, Endersby, Raelene, primary, Diaz, Alexander K., primary, Zhang, Junyuan, primary, Bax, Dorine A., primary, Carvalho, Diana, primary, Reis, Rui M., primary, Onar-Thomas, Arzu, primary, Broniscer, Alberto, primary, Wetmore, Cynthia, primary, Zhang, Jinghui, primary, Jones, Chris, primary, Ellison, David W., primary, and Baker, Suzanne J., primary

Published
2023
Full Text
View/download PDF

34. Supplementary Table 4 from Novel Oncogenic PDGFRA Mutations in Pediatric High-Grade Gliomas

Author

Paugh, Barbara S., primary, Zhu, Xiaoyan, primary, Qu, Chunxu, primary, Endersby, Raelene, primary, Diaz, Alexander K., primary, Zhang, Junyuan, primary, Bax, Dorine A., primary, Carvalho, Diana, primary, Reis, Rui M., primary, Onar-Thomas, Arzu, primary, Broniscer, Alberto, primary, Wetmore, Cynthia, primary, Zhang, Jinghui, primary, Jones, Chris, primary, Ellison, David W., primary, and Baker, Suzanne J., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Figure Legends and Figures from Novel Oncogenic PDGFRA Mutations in Pediatric High-Grade Gliomas

Author

Paugh, Barbara S., primary, Zhu, Xiaoyan, primary, Qu, Chunxu, primary, Endersby, Raelene, primary, Diaz, Alexander K., primary, Zhang, Junyuan, primary, Bax, Dorine A., primary, Carvalho, Diana, primary, Reis, Rui M., primary, Onar-Thomas, Arzu, primary, Broniscer, Alberto, primary, Wetmore, Cynthia, primary, Zhang, Jinghui, primary, Jones, Chris, primary, Ellison, David W., primary, and Baker, Suzanne J., primary

Published
2023
Full Text
View/download PDF

37. Contributors

Author

Abu-Arja, Rolla, primary, Aguilar-Bonilla, Ana, additional, Ahluwalia, Manmeet S., additional, Ali, Sheikh C., additional, Allen, Deborah H., additional, Alnahhas, Iyad, additional, Arnone, Gregory D., additional, Auquier, Pascal, additional, Avgeropoulos, Nicholas G., additional, Batich, Kristen A., additional, Baumstarck, Karine, additional, Bell, Susan D., additional, Benitez, Viviana, additional, Blumenthal, Deborah T., additional, Bornhorst, Miriam, additional, Boyer, Laurent, additional, Bramall, Alexa N., additional, Braun, Sarah, additional, Brem, Henry, additional, Broaddus, William C., additional, Broniscer, Alberto, additional, Butowski, Nicholas, additional, Cha, Soonmee, additional, Chamberlain, Marc C., additional, Chang, Susan, additional, Charest, Alain, additional, Chen, Zhi-Jian, additional, Chowdhary, Sajeel, additional, Clarke, Jennifer L., additional, Cohen, Adam L., additional, Colman, Howard, additional, Cooper, Michael, additional, Cotter, Jennifer, additional, Das, Sunit, additional, De, Kuntal, additional, De la Fuente, Macarena I., additional, Deo, Anand K., additional, Desjardins, Annick, additional, Dhall, Girish, additional, Doolittle, Nancy D., additional, Downey, Kira M., additional, Dunn, Gavin P., additional, Engelhard, Herbert H., additional, Ernoult, Emilie, additional, Everson, Richard G., additional, Fenstermaker, Robert A., additional, Ferry, Isabelle, additional, Figel, Sheila, additional, Fink, Karen L., additional, Finlay, Jonathan L., additional, Gernsback, Joanna E., additional, Giglio, Pierre, additional, Gorelick, Noah, additional, Haas-Kogan, Daphne, additional, Hachmann, Jan T., additional, Hashem, Hasan, additional, Henson, John W., additional, Huang, Sherri Y., additional, Huynh, Mai Anh, additional, Hwang, Eugene I., additional, Jackson, Eric, additional, Johanns, Tanner M., additional, Kahlon, Liron, additional, Kanojia, Deepak, additional, Karajannis, Matthias A., additional, Kaur, Balveen, additional, Kesari, Santosh, additional, Kilburn, Lindsay B., additional, Kim, Julius W., additional, Kline, Cassie, additional, Kolcun, John Paul G., additional, Komotar, Ricardo J., additional, Koshy, Matthew, additional, Kuzan-Fischer, Claudia M., additional, Lakka, Sajani S., additional, Lanoye, Autumn, additional, Lee, George P., additional, Lee, Eudocia Q., additional, Lesniak, Maciej S., additional, Liau, Linda M., additional, Loughan, Ashlee R., additional, Malkin, Mark G., additional, McCullough, Brendan J., additional, McGregor, John M., additional, Mehta, Ankit I., additional, Miller, Julie J., additional, Mohile, Nimish, additional, Moots, Paul L., additional, Mueller, Sabine, additional, Mukherjee, Joydeep, additional, Murillo, Tulio P., additional, Muroski, Megan E., additional, Neuwelt, Edward A., additional, Newton, Herbert B., additional, Nicholas, Martin K., additional, Oberheim Bush, Nancyann, additional, Okada, Hideho, additional, Omuro, Antonio M., additional, Packer, Roger J., additional, Paleologos, Nina A., additional, Panek, Wojciech K., additional, Pernal, Sebastian P., additional, Pickle, Emily Owens, additional, Pituch, Katarzyna C., additional, Pollack, Ian F., additional, Raizer, Jeffrey, additional, Rashidi, Aida, additional, Reardon, David A., additional, Reddy, Alyssa T., additional, Robert Kane, J., additional, Rutka, James T., additional, Sampson, John H., additional, Sattur, Mithun, additional, Scheck, Adrienne C., additional, Scott, Brian J., additional, See, Wendy L., additional, Shaikh, Nawal, additional, Sharma, Mayur, additional, Shokuhfar, Tolou, additional, Shroff, Seema, additional, Smith, Amy A., additional, Subramaniam, Subanandhini, additional, Suryadevara, Carter M., additional, Swanson, Kenneth D., additional, Tamrazi, Benita, additional, Taslimi, Shervin, additional, Teicher, Beverly, additional, Tran, Hung N., additional, Tyler, Betty, additional, Upadhyaya, Santhosh A., additional, Vega, Rafael A., additional, Venere, Monica, additional, Vogelbaum, Michael, additional, Von Ah, Diane, additional, Waissengrin, Barliz, additional, Waite, Emily S., additional, Wong, Eric T., additional, Xiao, Annie, additional, Yang, Jer-Yen, additional, Young, Jacob S., additional, Young Yoo, Ji, additional, and Zaky, Wafik, additional

Published
2018
Full Text
View/download PDF

39. TMET-09. LOSS OF MAT2A COMPROMISES METHIONINE METABOLISM AND REPRESENTS A VULNERABILITY IN H3K27M MUTANT GLIOMAS

Author

Halbert, Matthew, primary, Golbourn, Brian, additional, Halligan, Katharine, additional, Varadharajan, Srinidhi, additional, Krug, Brian, additional, Mbah, Nneka, additional, Kabir, Nisha, additional, Stanton, Ann-Catherine, additional, Locke, Abigail, additional, Casillo, Stephanie, additional, Zhao, Yanhua, additional, Sanders, Lauren, additional, Cheney, Allison, additional, Mullett, Steven, additional, Chen, Apeng, additional, Wassell, Michelle, additional, Andren, Anthony, additional, Perez, Jennifer, additional, Jane, Esther, additional, Premkumar, Daniel, additional, Koncar, Robert, additional, Mirhadi, Shideh, additional, McCarl, Lauren, additional, Chang, Yue-Fang, additional, Wu, Yigen, additional, Gatesman, Taylor, additional, Cruz, Andrea, additional, Zapotocky, Michal, additional, Hu, Baoli, additional, Kohanbash, Gary, additional, Wang, Xiuxing, additional, Vartanian, Alenoush, additional, Moran, Michael, additional, Lieberman, Frank, additional, Amankulor, Nduka, additional, Wendell, Stacy, additional, Vaske, Olena M, additional, Panigraphy, Ashok, additional, Felker, James, additional, Bertrand, Kelsey C, additional, Kleinman, Claudia, additional, Rich, Jeremy N, additional, Friedlander, Robert M, additional, Broniscer, Alberto, additional, Lyssiotis, Costas, additional, Jabado, Nada, additional, Pollack, Ian F, additional, Mack, Stephen C, additional, and Agnihotri, Sameer, additional

Published
2022
Full Text
View/download PDF

40. TMIC-54. THE ROLE OF TUMOR MICROENVIRONMENT DERIVED GROWTH FACTORS IN PEDIATRIC BRAIN TUMORS

Author

Cruz, Andrea, primary, Locke, Abigail, additional, Halligan, Katharine, additional, Sanders, Lauren, additional, Cheney, Allison, additional, Stanton, Ann-Catherine Jean, additional, Koncar, Robert, additional, Broniscer, Alberto, additional, Vaske, Olena M, additional, Pearce, Thomas, additional, Marker, Daniel, additional, Wiley, Clayton, additional, Mack, Stephen C, additional, Filbin, Mariella, additional, Pollack, Ian F, additional, and Agnihotri, Sameer, additional

Published
2022
Full Text
View/download PDF

46. Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor

Author

Upadhyaya, Santhosh A, primary, Campagne, Olivia, additional, Billups, Catherine A, additional, Orr, Brent A, additional, Onar-Thomas, Arzu, additional, Tatevossian, Ruth G, additional, Mostafavi, Roya, additional, Myers, Jason R, additional, Vinitsky, Anna, additional, Moreira, Daniel C, additional, Lindsay, Holly B, additional, Kilburn, Lindsay, additional, Baxter, Patricia, additional, Smith, Amy, additional, Crawford, John R, additional, Partap, Sonia, additional, Bendel, Anne E, additional, Aguilera, Dolly G, additional, Nichols, Kim E, additional, Rampersaud, Evadnie, additional, Ellison, David W, additional, Klimo, Paul, additional, Patay, Zoltan, additional, Robinson, Giles W, additional, Broniscer, Alberto, additional, Stewart, Clinton F, additional, Wetmore, Cynthia, additional, and Gajjar, Amar, additional

Published
2022
Full Text
View/download PDF

48. The seventh international RASopathies symposium: Pathways to a cure—expanding knowledge, enhancing research, and therapeutic discovery

Author

Hubrecht Institute with UMC, Cancer, Kontaridis, Maria I., Roberts, Amy E., Schill, Lisa, Schoyer, Lisa, Stronach, Beth, Andelfinger, Gregor, Aoki, Yoko, Axelrad, Marni E., Bakker, Annette, Bennett, Anton M., Broniscer, Alberto, Castel, Pau, Chang, Caitlin A., Cyganek, Lukas, Das, Tirtha K., den Hertog, Jeroen, Galperin, Emilia, Garg, Shruti, Gelb, Bruce D., Gordon, Kristiana, Green, Tamar, Gripp, Karen W., Itkin, Maxim, Kiuru, Maija, Korf, Bruce R., Livingstone, Jeff R., López-Juárez, Alejandro, Magoulas, Pilar L., Mansour, Sahar, Milner, Theresa, Parker, Elisabeth, Pierpont, Elizabeth I., Plouffe, Kevin, Rauen, Katherine A., Shankar, Suma P., Smith, Shane B., Stevenson, David A., Tartaglia, Marco, Van, Richard, Wagner, Morgan E., Ware, Stephanie M., Zenker, Martin, Hubrecht Institute with UMC, Cancer, Kontaridis, Maria I., Roberts, Amy E., Schill, Lisa, Schoyer, Lisa, Stronach, Beth, Andelfinger, Gregor, Aoki, Yoko, Axelrad, Marni E., Bakker, Annette, Bennett, Anton M., Broniscer, Alberto, Castel, Pau, Chang, Caitlin A., Cyganek, Lukas, Das, Tirtha K., den Hertog, Jeroen, Galperin, Emilia, Garg, Shruti, Gelb, Bruce D., Gordon, Kristiana, Green, Tamar, Gripp, Karen W., Itkin, Maxim, Kiuru, Maija, Korf, Bruce R., Livingstone, Jeff R., López-Juárez, Alejandro, Magoulas, Pilar L., Mansour, Sahar, Milner, Theresa, Parker, Elisabeth, Pierpont, Elizabeth I., Plouffe, Kevin, Rauen, Katherine A., Shankar, Suma P., Smith, Shane B., Stevenson, David A., Tartaglia, Marco, Van, Richard, Wagner, Morgan E., Ware, Stephanie M., and Zenker, Martin

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results